Top Page
Osteopore Ltd.
(Sydney:OSX)
Osteopore Ltd. (OSX) vs. iShares MSCI Australia ETF (EWA)
Osteopore Ltd. Business Overview & Revenue Model
Osteopore Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.89M | 2.81M | 2.22M | 1.69M | 1.11M | 1.50M |
| Gross Profit | 2.30M | 2.37M | 1.64M | 1.27M | 811.64K | 955.33K |
| EBITDA | -2.42M | -2.34M | -4.35M | -3.97M | -3.38M | -1.76M |
| Net Income | -3.26M | -3.35M | -4.87M | -4.22M | -3.62M | -1.95M |
Balance Sheet | ||||||
| Total Assets | 4.19M | 3.13M | 3.34M | 3.62M | 6.01M | 10.25M |
| Cash, Cash Equivalents and Short-Term Investments | 1.81M | 638.50K | 1.16M | 1.35M | 4.55M | 9.03M |
| Total Debt | 1.68M | 1.33M | 1.09M | 74.18K | 106.71K | 453.99K |
| Total Liabilities | 4.62M | 2.83M | 2.91M | 1.51M | 633.40K | 1.25M |
| Stockholders Equity | -423.65K | 306.22K | 432.60K | 2.11M | 5.37M | 9.00M |
Cash Flow | ||||||
| Free Cash Flow | -2.71M | -3.10M | -3.74M | -4.06M | -4.00M | -2.14M |
| Operating Cash Flow | -2.69M | -3.09M | -3.74M | -4.00M | -3.81M | -1.76M |
| Investing Cash Flow | -17.19K | -14.59K | -7.37K | -63.98K | -194.62K | -381.04K |
| Financing Cash Flow | 2.58M | 2.63M | 3.58M | 896.32K | -485.88K | 7.84M |
Osteopore Ltd. Technical Analysis
Osteopore Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | AU$255.32M | ― | -4.06% | ― | 20.36% | 64.81% | |
| ― | AU$12.40M | -2.67 | -27.84% | ― | 6.77% | -8.45% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | AU$42.73M | ― | -81.30% | ― | -36.68% | 79.41% | |
| ― | AU$2.61M | -0.46 | -487.52% | ― | 5.52% | 49.25% | |
| ― | AU$339.93M | -34.96 | -89.70% | ― | 42.05% | -0.84% | |
| ― | AU$107.88M | -13.24 | -47.98% | ― | 700.00% | 26.88% |
Osteopore Ltd. Corporate Events
Osteopore Limited has announced a collaboration with Tan Tock Seng Hospital to develop a novel implant for treating avascular necrosis (AVN) at the hip joint. This partnership, funded by a SGD 50,000 MedTech grant from NHG Health, aims to enhance outcomes for core decompression in AVN and could potentially reduce healthcare costs. The AVN treatment market is projected to grow significantly, reaching USD 10.2 billion by 2030, driven by increased awareness and earlier diagnosis.
Osteopore Limited has launched OsteoRx, a special purpose vehicle aimed at advancing cellular regenerative medicine, with an initial investment of AUD 0.5 million. This strategic move involves a partnership with renowned scientists and a controlling stake in RxCell Inc, enhancing Osteopore’s leadership in the regenerative medicine sector and expanding its influence in the growing stem cell market.
Osteopore Limited reported a 6% increase in revenue for the half-year ended 30 June 2025, despite a slight rise in net loss after tax. The increased losses were primarily due to higher product development and laboratory expenses, driven by investments in compliance-related activities and expanding market presence. The company managed to offset some of these costs by reducing sales, marketing, and administrative expenses. Additionally, finance costs decreased following the settlement of a bridging loan, reflecting improved financial management. The company’s focus on high-growth business segments and maintaining cost efficiency is indicative of its strategic positioning in the medical technology industry.
Osteopore Limited has initiated a clinical study in collaboration with Universiti Malaya to explore the efficacy of its polycaprolactone membrane compared to traditional collagen membranes in socket healing post-third molar surgery. This study, involving 18 patients, aims to address common post-operative issues such as pain and swelling, potentially improving periodontal health. The study’s outcome could position Osteopore’s product as a superior alternative due to its gradual degradation and enhanced barrier function, which may significantly impact the dental surgery field.
Osteopore Ltd. has successfully won tender bids to supply its orthopaedic products to two major public hospitals in Vietnam, marking a significant entry into the Vietnamese market. This development is expected to enhance Osteopore’s market position in the Asia Pacific region, particularly in the high-growth high tibial osteotomy and bone grafting markets, which are projected to grow significantly. The company plans to work with its distribution partner to finalize logistics and supply arrangements, aiming to capitalize on the growing demand driven by Vietnam’s aging population and increasing prevalence of orthopaedic conditions.
Osteopore Ltd. has announced the quotation of 30,120,481 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of July 31, 2025. This move is expected to enhance the company’s financial flexibility and market presence, potentially impacting its operational capabilities and offering new opportunities for stakeholders.
Osteopore Limited has reported a record quarterly revenue of AUD 835K for Q2 CY25, marking a 15% increase quarter-on-quarter and an 11% rise year-on-year. The company has also secured EU MDR clearance for its custom orthopaedic and cranial implants, which is expected to open new revenue streams and enhance its market presence in the European Union.
Osteopore Limited has reported significant progress following its Exclusive Distribution Agreement with Zimmer Biomet, a global medical technology leader. Over the first 12 months of the partnership, sales of Osteopore’s craniofacial products in Europe, Australia, and Hong Kong have tripled compared to the previous year. This growth highlights the company’s resilience in manufacturing and its ability to scale operations effectively. With recent European approval for custom-made cranioplasty implants, Osteopore anticipates increased market traction and plans to expand into new markets in collaboration with Zimmer Biomet.